Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 8;14(5):603.
doi: 10.3390/life14050603.

Everolimus Treatment for Chronic Lung Allograft Dysfunction in Lung Transplantation

David Iturbe-Fernández  1 , Alicia de Pablo Gafas  2 , Víctor Manuel Mora Cuesta  1 , Rodrigo Alonso Moralejo  2 , Carlos Andrés Quezada Loaiza  2   3 , Virginia Pérez González  2 , Daniel López-Padilla  4 , José M Cifrián  1
Affiliations

Everolimus Treatment for Chronic Lung Allograft Dysfunction in Lung Transplantation

David Iturbe-Fernández et al. Life (Basel). .

Abstract

Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD).

Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment.

Results: Fifty-seven patients were included in this study. The variation in the FEV1 was -102.7 (149.6) mL/month before starting everolimus compared to -44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and -7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5-25.1) months.

Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients.

Keywords: chronic lung allograft dysfunction; everolimus; lung transplantation.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Slope of FEV1 variation before and after everolimus treatment.
See this image and copyright information in PMC

References

    1. Perch M., Hayes D., Cherikh W.S., Zuckermann A., Harhay M.O., Hsich E., Potena L., Sadavarte A., Lindblad K., Singh T.P., et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J. Heart Lung Transplant. 2022;41:1335–1347. doi: 10.1016/j.healun.2022.08.007. - DOI - PMC - PubMed
    1. Verleden G.M., Glanville A.R., Lease E.D., Fisher A.J., Calabrese F., Corris P.A., Ensor C.R., Gottlieb J., Hachem R.R., Lama V., et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT. J. Heart Lung Transplant. 2019;38:493–503. doi: 10.1016/j.healun.2019.03.009. - DOI - PubMed
    1. Verleden G.M., Verleden S.E., Vos R., De Vleeschauwer S.I., Dupont L.J., Van Raemdonck D.E., Vanaudenaerde B.M. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A pilot study. Transpl. Int. 2011;24:651–656. doi: 10.1111/j.1432-2277.2011.01248.x. - DOI - PubMed
    1. Vos R., Wuyts W.A., Gheysens O., Goffin K.E., Schaevers V., Verleden S.E., Van Herck A., Sacreas A., Heigl T., McDonough J.E., et al. Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series. Am. J. Transplant. 2018;18:3045–3059. doi: 10.1111/ajt.15019. - DOI - PubMed
    1. Fisher A.J., Rutherford R.M., Bozzino J., Parry G., Dark J.H., Corris P.A. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant. 2005;5:537–543. doi: 10.1111/j.1600-6143.2004.00709.x. - DOI - PubMed

LinkOut - more resources